

<b>TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT</b> (Under 37 CFR 1.97(b) or 1.97(c))			Docket No. RLL-159US
In Re Application Of: <b>Kumar et al.</b>			
Serial No. 10/009,230	Filing Date 5/25/2000	Examiner Unknown	Group Art Unit Unknown
Title: <b>AMORPHOUS FORM OF FEXOFENADINE HYDROCHLORIDE</b>		<b>RECEIVED</b> AUG 01 2002 TECH CENTER 1600/2900	
<p>Address to:  Assistant Commissioner for Patents  Washington, D.C. 20231</p> <p><b>37 CFR 1.97(b)</b></p> <p>1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.</p> <p style="text-align: center;"><b>37 CFR 1.97(c)</b></p> <p>2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:</p> <p style="padding-left: 40px;"><input type="checkbox"/> the statement specified in 37 CFR 1.97(e);</p> <p style="text-align: center;"><b>OR</b></p> <p style="padding-left: 40px;"><input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).</p>			

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
RLL-159US

In Re Application: **Kumar et al.**

Serial No.

10/009,230

Filing Date

5/25/2000


Examiner

Unknown

Group Art Unit

Unknown

**AMORPHOUS FORM OF FEXOFENADINE HYDROCHLORIDE**



**RECEIVED**  
AUG 01 2002

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☐ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. \_\_\_\_\_ as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of \_\_\_\_\_
- ☐ Credit any overpayment.
- ☐ Charge any additional fee required.

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. \_\_\_\_\_) on \_\_\_\_\_


(Date)

Signature

Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**

I certify that this document and fee is being deposited on June 27, 2002 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.



Signature of Person Mailing Correspondence

Christine Kenedy

Typed or Printed Name of Person Mailing Certificate

**\*This certificate may only be used if paying by deposit account.**



Signature

Dated: 27 June 2002

**Jayadeep R. Deshmukh, Esq., Reg. No. 34,507**  
**Ranbaxy Laboratories Limited**  
**600 College Road East, Suite 2100**  
**Princeton, New Jersey 08540**  
**Telephone: (609) 720-5608**  
**Facsimile: (609) 514-9779**

CC: